Holen Sie sich die Stockscreener-App
6.46
2.70%
0.17
Handel nachbörslich:
6.61
0.15
+2.32%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt NEO?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$6.29
Offen:
$6.33
24-Stunden-Volumen:
2.88M
Relative Volume:
1.33
Marktkapitalisierung:
$831.37M
Einnahmen:
$628.25M
Nettoeinkommen (Verlust:
$-78.55M
KGV:
-10.42
EPS:
-0.62
Netto-Cashflow:
$-29.73M
1W Leistung:
+4.03%
1M Leistung:
-10.03%
6M Leistung:
-57.44%
1J Leistung:
-56.59%
1-Tages-Spanne:
$6.205
$6.61
1-Wochen-Bereich:
$6.205
$6.65
52-Wochen-Spanne:
$6.08
$19.11
Neogenomics Inc Stock (NEO) Company Profile
Firmenname
Neogenomics Inc
Sektor
Branche
Telefon
(239) 768-0600
Adresse
9490 NEOGENOMICS WAY, FORT MYERS, FL
Vergleichen Sie NEO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
6.46 | 809.49M | 628.25M | -78.55M | -29.73M | -0.62 |
|
TMO
Thermo Fisher Scientific Inc
|
484.96 | 180.56B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
202.94 | 147.13B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
566.50 | 45.45B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
119.54 | 34.14B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
197.76 | 33.86B | 15.50B | 1.33B | 2.16B | 7.34 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-15 | Eingeleitet | Guggenheim | Neutral |
| 2025-04-30 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-01-13 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2024-12-10 | Eingeleitet | Jefferies | Buy |
| 2024-05-01 | Fortgesetzt | Craig Hallum | Buy |
| 2023-12-29 | Bestätigt | BTIG Research | Buy |
| 2023-08-21 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | Hochstufung | BTIG Research | Neutral → Buy |
| 2023-02-24 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-02-01 | Hochstufung | Needham | Hold → Buy |
| 2022-08-26 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-22 | Herabstufung | Needham | Buy → Hold |
| 2022-06-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-03-29 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-29 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | Fortgesetzt | Stephens | Overweight |
| 2021-12-16 | Eingeleitet | Cowen | Outperform |
| 2021-11-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-02-25 | Fortgesetzt | Needham | Buy |
| 2021-02-25 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-12-11 | Fortgesetzt | BTIG Research | Buy |
| 2020-10-28 | Bestätigt | Needham | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-08-28 | Eingeleitet | Guggenheim | Buy |
| 2020-07-29 | Bestätigt | Needham | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Buy |
| 2020-04-21 | Fortgesetzt | Stephens | Overweight |
| 2020-03-02 | Fortgesetzt | Craig Hallum | Buy |
| 2020-02-28 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | Herabstufung | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | Bestätigt | Needham | Buy |
| 2019-05-01 | Bestätigt | Needham | Buy |
| 2019-03-29 | Bestätigt | Needham | Buy |
| 2019-01-03 | Eingeleitet | Needham | Buy |
| 2018-10-24 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | Eingeleitet | Leerink Partners | Outperform |
| 2018-05-02 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | Herabstufung | BTIG Research | Buy → Neutral |
| 2017-08-24 | Eingeleitet | Gabelli & Co | Buy |
| 2016-12-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Neogenomics Inc Aktie (NEO) Neueste Nachrichten
NeoGenomics Wants Jury Trial In Natera DNA Test Patent Fight - Law360
What institutional investors are buying NeoGenomics Inc. stockBreakout Stocks Signals For Fast Growth - jammulinksnews.com
NeoGenomics (NEO): Is This a Buy-the-Dip Opportunity in the Precision Oncology Diagnostics Sector? - AInvest
NeoGenomics Q2 2025 Earnings Preview - MSN
What are the latest earnings results for NeoGenomics Inc.Strong return on assets - jammulinksnews.com
How many analysts rate NeoGenomics Inc. as a “Buy”Maximize gains with professional stock picks - jammulinksnews.com
NeoGenomics (NEO): A Buy-the-Dip Opportunity in Oncology Diagnostics or a Risky Bet? - AInvest
How volatile is NeoGenomics Inc. stock compared to the marketBuild wealth faster with consistent growth stocks - jammulinksnews.com
NeoGenomics (NEO) Reports Q2: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
What are the technical indicators suggesting about NeoGenomics Inc.Maximize your portfolio’s growth potential - jammulinksnews.com
What is the risk reward ratio of investing in NeoGenomics Inc. stockFree Stock Market Return Analysis - jammulinksnews.com
When is NeoGenomics Inc. stock expected to show significant growthDiscover hidden gems in the stock market - jammulinksnews.com
How strong is NeoGenomics Inc. company’s balance sheetGet timely alerts on market movers - jammulinksnews.com
What is the dividend policy of NeoGenomics Inc. stockFree Buy/Sell Signal Notifications - jammulinksnews.com
What is NeoGenomics Inc. company’s growth strategyFree Consultation - jammulinksnews.com
Is NeoGenomics Inc. stock overvalued or undervaluedBuild a winning portfolio with smart picks - jammulinksnews.com
What drives NeoGenomics Inc. stock priceFree Predictions - PrintWeekIndia
Is NeoGenomics Inc. a good long term investmentRapid profit acceleration - PrintWeekIndia
NeoGenomics Inc. Stock Analysis and ForecastTremendous growth potential - PrintWeekIndia
Will NeoGenomics Inc. stock benefit from AI tech trendsRapid wealth multiplication - jammulinksnews.com
What analysts say about NeoGenomics Inc. stockExceptional trading performance - PrintWeekIndia
NeoGenomics (NEO) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Personalized ctDNA monitoring in metastatic HR+/HER2− breast cancer patients during endocrine and CDK4/6 inhibitor therapy - Nature
Bank of America Securities Sticks to Their Hold Rating for NeoGenomics (NEO) - The Globe and Mail
Neogenomics Shares Plunge 7.14% Amid Earnings Woes - AInvest
Moderna, Lantheus, Centene, AMN Healthcare Services, and NeoGenomics Shares Plummet, What You Need To Know - Yahoo Finance
Pathological Examination Market Gaining Momentum in Cancer - openPR.com
Finanzdaten der Neogenomics Inc-Aktie (NEO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):